SASKATOON, Saskatchewan–(BUSINESS WIRE)–ZYUS Life Sciences Inc. (“ZYUS”), a Canadian life sciences company leading scientific research and development in herbal medicine, today announced that the company’s Canadian manufacturing facility has received the EU-Good Manufacturing Practice (“EU- GMP certification”) award. Obtaining this certification is an essential requirement for exporting cannabinoid oil formulations to the European Union (EU). It also independently verifies that ZYUS manufacturing processes have been developed to produce clinical trial drug candidates and commercial products that meet stringent EU-GMP standards.
EU-GMP certification, an internationally recognized certification granted only to companies whose manufacturing procedures and facilities demonstrate a high degree of consistency, precision and quality throughout all stages of production, provides ZYUS with the opportunity to pursue international distribution opportunities in the EU, as well as in other global markets that accept EU-GMP certification for market access, such as certain countries located in Latin America and Oceania.
ZYUS’ EU-GMP certification was granted by Portugal’s Infarmed — National Medicines and Health Products Authority, IP — which evaluates, authorizes and regulates medicines and medical devices for the protection of public health. Infarmed continues to operate in several areas at the national and European levels, and during its in-depth audit of ZYUS’ pharmaceutical-grade cannabinoid extraction facility, ZYUS demonstrated that its state-of-the-art Canadian site, as well as its manufacturing facilities and its extensive processes and documentation has consistently met or exceeded stringent EU-GMP certification requirements as a drug manufacturer.
“At ZYUS, we are committed to providing patients in Canada and around the world with high-quality cannabinoid formulations backed by our team’s decades-long leadership in the field of medical cannabinoids,” said ZYUS CEO. , Brent Zettl. “By achieving EU-GMP certification, we can now begin executing our well-developed plans to expand into a number of key international markets as we embark on our strategy of rapid global growth.”
ZYUS has already established several pharmaceutical distribution and sales agreements to supply medical cannabinoids to several international markets. Achieving this certification marks an important milestone in ZYUS’ journey to improving a growing number of patient outcomes, and another milestone in the company’s global expansion.
About ZYUS Life Sciences Inc.
ZYUS is a Canadian life sciences company focused on the development and global commercialization of innovative cannabinoid-based therapeutics and product candidates. Through clinical research and intellectual property development, we intend to provide patients worldwide with high quality cannabinoid oils, capsules, topical creams and other therapeutic products and product candidates. . ZYUS’ vision is to elevate cannabinoids as the standard of care and expand the potential of protein-based formulations in pursuit of a transformational impact on patients’ lives. ZYUS: Advancing the science of wellness. To visit www.zyus.com.
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of ZYUS to be materially different from any future results, performance or achievements expressed or implied by the statements. prospective. These forward-looking statements include, but are not limited to, expectations regarding our business plans, research activities, product lines and patient services.
Often, but not always, forward-looking statements can be identified by the use of words such as “expects”, “expects”, “expects”, “anticipates”, “believes”, ” intends to”, “estimates”, “predicts”. , “continuing”, “potential”, “targeted”, “anticipates”, “possible” and similar expressions, or statements that events, conditions or results “will”, “may”, “might” , “would” or “should” occur or be realized, or the negative form of these terms or other comparable terms. Forward-looking statements are based on certain assumptions, including that all necessary approvals and permits will be obtained, ZYUS’ ability to expand into international markets, and ZYUS’ ability to provide patients with cannabinoid formulations of high quality, and are subject to various known regulations and unknown risks and uncertainties, many of which are beyond the control of the Company and cannot be predicted or quantified and, therefore, actual results may differ materially from those expressed or implied by these forward-looking statements.
Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Because forward-looking statements and information relate to future events and conditions, they, by their very nature, involve inherent risks and uncertainties.
Readers are cautioned that the above list of factors is not exhaustive. The forward-looking statements contained in this press release are made as of the date of this release and, accordingly, are subject to change after such date. ZYUS undertakes no obligation to update or revise any forward-looking statements or information, whether written or oral, which may be made from time to time by us or on our behalf, except as required by applicable law.
#ZYUS #Life #Sciences #Awarded #EUGMP #Certification #Enables #Expansion #Rapidly #Growing #Global #Medical #Cannabinoids #Markets